GHK-Cu Peptide

What is GHK-Cu?

GHK-Cu stands for glycyl-L-histidyl-L-lysine-copper(II). It is a tripeptide that naturally binds copper and is found in human plasma, saliva, and urine. Researcher Loren Pickart first identified it in the 1970s while investigating why young plasma caused aging liver tissue to recover its metabolic function. The active agent, it turned out, was this small copper-binding sequence.

Plasma concentrations are highest in early adulthood, around 200 ng/mL at age 20, and drop to roughly 80 ng/mL by age 60. That decline tracks closely with several age-related changes in tissue repair capacity, skin quality, and wound healing speed, which is what drove decades of research into GHK-Cu as a potential intervention.

Unlike many peptides in the research space that target a single receptor, GHK-Cu is notable for the breadth of its gene-regulatory effect. Pickart's later genomics work found it modulates the expression of over 4,000 human genes, with particularly strong signals in pathways governing extracellular matrix repair, antioxidant defense, and inflammation resolution.

Mechanism of action

GHK-Cu works through several overlapping pathways rather than one clean on/off switch.

Collagen and extracellular matrix

The best-documented effect is on connective tissue synthesis. GHK-Cu stimulates fibroblasts to produce collagen, elastin, and glycosaminoglycans. It activates the TGF-beta pathway to upregulate collagen I and III, and simultaneously promotes the activity of matrix metalloproteinases that break down damaged, disorganized collagen. The result is net replacement of degraded tissue with new, organized matrix rather than scar tissue. This is why wound-healing studies consistently show faster and better-quality repair with GHK-Cu compared to control conditions.

Angiogenesis

GHK-Cu upregulates vascular endothelial growth factor (VEGF), which promotes the formation of new capillaries. Better capillary density means more oxygen and nutrient delivery to the repair site. This mechanism overlaps with what makes BPC-157 and TB-500 effective for tissue injury recovery, though GHK-Cu drives it through the copper-dependent enzymatic pathway rather than through growth factor receptor signaling.

Antioxidant and anti-inflammatory

GHK-Cu activates superoxide dismutase (SOD), one of the primary intracellular antioxidant enzymes. It also suppresses pro-inflammatory cytokines, including TNF-alpha, IL-1, and IL-6, while leaving the acute inflammatory phase largely intact. The net effect is faster transition from the inflammatory to the proliferative phase of healing, which shortens recovery time without suppressing the initial immune response that clears damaged tissue.

Nerve growth factor

Several studies have found GHK-Cu upregulates nerve growth factor (NGF) expression, which supports peripheral nerve repair and may partly explain interest in its neuroprotective potential. This is an earlier-stage research area than the skin and wound data.

What the research shows

Wound healing

This is where the evidence base is strongest. Animal studies dating back decades consistently show GHK-Cu accelerates wound contraction, improves tensile strength of healed tissue, and promotes capillary formation in the wound bed. One frequently cited rat study found GHK-Cu-treated wounds closed 30 percent faster than controls and showed better collagen organization at closure.

Human data is more limited but directionally consistent. Several pilot studies using topical GHK-Cu on post-surgical wounds and chronic wounds found improved healing rates and reduced scarring. The topical route is less efficient than subcutaneous because the peptide needs to cross the skin barrier, but the effect is measurable.

Skin biology and anti-aging

GHK-Cu is already used commercially in topical cosmeceuticals, and there is a reasonable evidence base for topical application reducing fine lines, improving skin thickness and elasticity, and promoting an even skin tone. These effects are attributed to the collagen-rebuilding mechanism plus a reduction in matrix metalloproteinases that degrade existing collagen during normal aging.

A 2015 review of GHK-Cu in skin biology noted consistent findings across multiple labs: increased keratinocyte proliferation, upregulation of decorin and fibronectin, and reduction of UV-induced oxidative damage markers. Injectable formulations used in research settings are expected to have a systemic effect that supplements the local topical benefit, though controlled human trials on the injectable route for skin aging specifically are limited.

Hair follicle research

Hair follicle data for GHK-Cu is compelling at the preclinical level. Studies show it enlarges follicle size, increases hair shaft diameter, and extends the anagen (growth) phase while shortening the telogen (resting) phase. One comparison study found GHK-Cu performed similarly to 2% minoxidil in inducing anagen re-entry in mouse follicles, which is a higher bar than most peptide comparisons.

The mechanism is partly through activating the Wnt/beta-catenin pathway that governs follicle cycling, and partly through improving blood supply to the follicle via VEGF. The combination of those two effects distinguishes GHK-Cu from simple DHT-blocking approaches. It is not replacing finasteride in a hair loss protocol, but researchers working on follicle preservation and regeneration regularly include it.

Neuroprotective potential

More recent research has looked at GHK-Cu in the context of cognitive aging and neurodegeneration. Gene expression analyses suggest it upregulates genes associated with neuroprotection and downregulates those associated with Alzheimer's-related pathways, including amyloid processing genes. These are early in vitro and bioinformatic findings, not clinical outcomes data, but they have attracted meaningful academic attention.

GHK-Cu vs. other recovery and anti-aging peptides

GHK-Cu and BPC-157 are commonly studied together because they complement rather than duplicate each other. BPC-157 accelerates acute repair through blood vessel formation and tendon-specific growth factor signals. GHK-Cu handles the matrix remodeling and collagen quality work that follows. For skin-focused or hair-focused research protocols, GHK-Cu is often the primary compound with a GH-secretagogue like CJC-1295 added for systemic anabolic support.

Research dosing context

Preclinical and early human research most commonly uses subcutaneous injection of 1 to 2 mg, two to three times per week. Some wound-healing protocols administer it daily for shorter durations, typically two to four weeks. Longer research cycles generally include rest periods of similar length to the active phase.

GHK-Cu has a short plasma half-life, around 30 minutes for the synthetic tripeptide, which is why frequent, smaller doses are preferred over infrequent large ones in research settings. The peptide does not accumulate; each dose provides a pulse of signaling activity rather than a sustained blood level.

Reconstitution follows the same process as other lyophilized peptides: bacteriostatic water, gentle swirl without shaking, refrigerated storage after reconstitution. See the reconstitution guide for detailed steps. For storage of unmixed vials, the peptide storage guide covers temperature and light exposure best practices.

Safety and tolerability

GHK-Cu has a strong preclinical safety profile. Published research at research-relevant doses shows no significant hepatotoxicity, nephrotoxicity, or immune suppression. Copper is an essential trace mineral and the amount delivered at these doses is small relative to dietary intake.

The most commonly noted injection-site effect is a mild blue or green discoloration from the copper content. This is harmless and resolves within a day or two. It is simply the copper compound being visible under the skin temporarily.

Theoretical concerns about long-term copper accumulation exist but have not been observed in research at standard doses. Individuals with Wilson's disease or other copper metabolism disorders should not research GHK-Cu.

Forms: injectable vs. topical

Topical GHK-Cu is available in consumer cosmetic products from brands including The Ordinary, SkinMedica, and others. These work, but skin penetration limits how much reaches the dermal layer and none of it reaches systemic circulation. They are a reasonable option for surface-level skin goals but cannot replicate the wound-healing or hair follicle data from systemic administration.

Injectable GHK-Cu sold for research purposes is the lyophilized peptide form reconstituted in bacteriostatic water and administered subcutaneously. This is the form used in most of the wound healing and follicle studies and delivers the peptide systemically rather than relying on transdermal penetration.

Stacking context

For researchers focused on skin repair and anti-aging, a common starting combination is GHK-Cu with BPC-157 for overlapping wound-healing support. Those adding a growth hormone axis angle stack it with CJC-1295 plus ipamorelin, since GH has its own collagen-stimulating effects that work additively with GHK-Cu's direct matrix action. The stack builder quiz can map out which combination fits a specific research goal.

For hair-focused protocols, GHK-Cu is often paired with a GH-secretagogue to combine the follicle-cycling effect with improved IGF-1 signaling to the scalp, and sometimes with a low-dose BPC-157 to support the vascular component.

Sourcing

GHK-Cu is widely available from research peptide vendors. Key things to check are certificate of analysis (COA) confirming purity and sequence verification, cold-chain shipping (lyophilized peptides tolerate transit better than reconstituted, but temperature matters), and whether the vendor publishes third-party testing results rather than in-house only.

The vendor comparison page has current information on which vendors carry GHK-Cu with documented COAs.

Frequently asked questions